Ph 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234
← catalyst calendarNCT07453602 · readout ≤ 620 d
Sponsored by Arcutis Biotherapeutics, Inc. (industry) · ARQT — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
125estimated
Sites
2
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-03-02 | actual | When the study began enrolling |
| Primary completion | Apr 2028 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Apr 2028 | estimated | The whole study's end, after follow-up |
| First posted | 2026-03-06 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Atopic Dermatitis (AD)
- Eczema
Interventions
- Biological: ARQ-234
- Drug: Placebo
Primary outcomes
what the primary-completion date above is the date OFNumber and percentage of participants who experience an adverse event (AE) or serious adverse event (SAE)
measured From screening to the last follow up visit for each study part (Part A: 16 weeks, Part B: 30 weeks, Part C: 30 weeks)
Percent change from Baseline in the Eczema Area and Severity Index (EASI) score, a validated measure of disease severity in atopic dermatitis.
measured From Baseline to Week 16
Permalink · ARQT's whole pipeline · Catalyst calendar · Every registered study · What changed